Five Prime Welcomes Garry Nicholson to Board of Directors
May 15 2017 - 4:05PM
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage
biotechnology company focused on discovering and developing
innovative immuno-oncology protein therapeutics, today announced
the appointment of Garry Nicholson to its board of directors.
“Garry is a highly regarded and accomplished leader
in the global oncology market and he brings extensive expertise in
product development and commercialization,” said Lewis T. "Rusty"
Williams, M.D., Ph.D., president, chief executive officer and
chairman of the board of Five Prime. “We will benefit from Garry’s
deep experience in oncology product development, marketing, sales
and general management on a worldwide basis as Five Prime continues
to advance toward late-stage clinical development.”
Mr. Nicholson served as President and Chief
Executive Officer of XTuit Pharmaceuticals, Inc., from September
2015 to October 2016. From May 2008 to March 2015, Mr. Nicholson
served at Pfizer Inc. as President, Pfizer Oncology. Prior to
joining Pfizer, Mr. Nicholson worked at Eli Lilly and Company where
he held roles of increasing responsibility, most recently as the
Global Oncology Platform Leader. Mr. Nicholson currently serves on
the board of directors of Tesaro, Inc., a public pharmaceutical
company. Mr. Nicholson received a B.S. in Pharmacy from the
University of North Carolina at Chapel Hill and an M.B.A. from the
University of South Carolina.
About Five PrimeFive Prime
Therapeutics, Inc. discovers and develops innovative therapeutics
to improve the lives of patients with serious diseases. Five
Prime's comprehensive discovery platform, which encompasses
virtually every medically relevant extracellular protein, positions
it to explore pathways in cancer, inflammation and their
intersection in immuno-oncology, an area with significant
therapeutic potential and a growing focus of the company's R&D
activities. Five Prime has entered into strategic collaborations
with leading global pharmaceutical companies and has promising
product candidates in clinical and late preclinical development.
For more information, please visit www.fiveprime.com.
Cautionary Note on Forward-looking
StatementsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as "may," "will," "expect," "plan,"
"anticipate," "estimate," "intend" and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking
statements. These forward-looking statements are based on Five
Prime's expectations and assumptions as of the date of this press
release. Each of these forward-looking statements involves risks
and uncertainties. Actual results may differ materially from these
forward-looking statements. Factors that may cause actual results
to differ from those expressed or implied in the forward-looking
statements in this press release are discussed in Five Prime's
filings with the U.S. Securities and Exchange Commission, including
the "Risk Factors" contained therein. Except as required by law,
Five Prime assumes no obligation to update any forward-looking
statements contained herein to reflect any change in expectations,
even as new information becomes available.
Heather Rowe
Investor Relations
415-365-5737
heather.rowe@fiveprime.com
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024